<DOC>
	<DOCNO>NCT01364428</DOCNO>
	<brief_summary>This trial conduct United States America ( USA ) . The aim trial compare efficacy safety two different formulation insulin degludec ( IDeg ) subject type 2 diabetes .</brief_summary>
	<brief_title>Comparison Two Insulin Degludec Formulations Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Type 2 diabetes ( diagnose clinically ) minimum 24 week prior randomisation ( visit 2 ) Current treatment basalonly insulin ( prandial insulin ) consist either insulin detemir daily ( OD ) , insulin glargine OD neutral protamine hagedorn ( NPH ) insulin OD/twice daily ( BID ) least 12 week prior randomisation ( visit 2 ) , combination stable dos OAD ( ) ( metformin , insulin secretagogue ( sulfonylurea glinide ) , alphaglucosidase inhibitor , pioglitazone dipeptidyl peptidase IV ( DPPIV ) inhibitor approve ( accord label ) dose combination . Stable OAD dos define unchanged dos least 12 week prior randomisation ( visit 2 ) HbA1c ( glycosylated haemoglobin ) 7.010.0 % ( inclusive ) central laboratory analysis Body mass index ( BMI ) equal 45 kg/m^2 Ability willingness adhere protocol include selfmeasured plasma glucose ( SMPG ) accord protocol Treatment rosiglitazone within last 12 week prior randomisation ( visit 2 ) Treatment glucagon like peptide1 ( GLP1 ) receptor agonist within last 12 week prior randomisation ( visit 2 ) Recurrent severe hypoglycaemia ( one severe hypoglycaemic event last 12 month ) hypoglycaemic unawareness judge Investigator ( trial physician ) Previous participation trial . Participation define randomise . Rescreening allowed recruitment period Known suspect hypersensitivity trial product relate product The receipt investigational drug within 4 week prior randomisation ( visit 2 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>